Mallinckrodt, a little-known drug maker that made headlines recently for various scandals, has resigned from the largest pharmaceutical industry trade group, which is planning steps to convince the public that its members are devoted to research activities.

The move comes as the Pharmaceutical Research & Manufacturers of America tries to respond to ongoing controversy over pricing. The trade group is undergoing what it called a “comprehensive review” of membership criteria in hopes of dispelling criticism that drug makers are price gouging.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy